Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Nuciforo P, Townend J, Piccart MJ, Fielding S, et al. Eur J Cancer 2022;181:92-101.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nuciforo P, Townend J, Piccart MJ, Fielding S, et al. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer 2022;181:92-101.
PMID: 36641898